These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38953706)

  • 1. The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis.
    Charlton M; Tonnu-Mihara I; Teng CC; Zhou Z; Asefaha F; Luthra R; Hoovler A; Uzoigwe C
    J Med Econ; 2024; 27(1):919-930. PubMed ID: 38953706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the burden of illness of metabolic dysfunction-associated steatohepatitis in a large managed care population: The ETHEREAL Study.
    Charlton M; Tonnu-Mihara I; Teng CC; Zhou Z; Asefaha F; Luthra R; Articolo A; Hoovler A; Uzoigwe C
    J Manag Care Spec Pharm; 2024 Dec; 30(12):1414-1430. PubMed ID: 39331041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study.
    Fishman JC; Qian C; Kim Y; Rochon H; Szabo SM; Sun R; Charlton M
    J Manag Care Spec Pharm; 2024 Sep; 30(9):929-941. PubMed ID: 38845444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH.
    Younossi ZM; Mangla KK; Chandramouli AS; Lazarus JV
    Hepatol Commun; 2024 Aug; 8(8):. PubMed ID: 39037377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis.
    Samant S; Chen E; Carias C; Kujawski SA
    J Med Econ; 2024; 27(1):1046-1052. PubMed ID: 39092467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care resource use and costs in patients with food allergies: a United States insurance claims database analysis.
    Sindher SB; Warren C; Ciaccio C; Seetasith A; Liu Y; Gupta S; Gupta R
    J Med Econ; 2024; 27(1):1027-1035. PubMed ID: 39087236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis.
    Tapper EB; Bonafede M; Fishman J; Dodge S; Miller K; Zeng N; Lewandowski D; Bogdanov A
    J Med Econ; 2023; 26(1):348-356. PubMed ID: 36866575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIS2+
    Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
    Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
    J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of respiratory syncytial virus in adults in Germany - a health claims analysis between 2015 and 2018.
    Huebbe B; Mocek A; Manz KC; Vivirito A; Bayer LJ; Norris R; Schiffner-Rohe J; von Eiff C; Lade C
    J Med Econ; 2024; 27(1):1063-1075. PubMed ID: 39105626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 16. Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity.
    Riaz F; Umashankar K; Marchlewicz EH; Zhang K; Khandelwal N; Sanchirico M
    J Med Econ; 2024; 27(1):849-857. PubMed ID: 38885115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
    Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
    J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: a retrospective claims analysis (2015-2020).
    Jun MP; Mutebi A; Chhibber A; Liang C; Keshishian A; Wang A; Rivas Navarro F; Kalsekar A; He J; Wang T
    J Med Econ; 2024; 27(1):1157-1167. PubMed ID: 39254695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.